

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7396428

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NORMAN R. WAINWRIGHT	05/03/2022
MASAKAZU TSUCHIYA	05/05/2022
JOHN DUBCZAK	05/03/2022
FOSTER T. JORDAN	06/10/2022
RECEIVING PARTY DATA	
Name:	CHARLES RIVER LABORATORIES, INC.
Street Address:	251 BALLARDVALE STREET
City:	WILMINGTON
State/Country:	MASSACHUSETTS
Postal Code:	01887-1000
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17650803
CORRESPONDENCE DATA	
Fax Number:	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 570-1000
Email:	us-patentbos@goodwinlaw.com, ckomm@goodwinlaw.com, tayube@goodwinlaw.com
Correspondent Name:	GOODWIN PROCTER LLP
Address Line 1:	100 NORTHERN AVENUE
Address Line 2:	IP DOCKETING DEPT./7TH FL
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	CHR-047
NAME OF SUBMITTER:	CRYSTAL A. KOMM
SIGNATURE:	/Crystal A. Komm/
DATE SIGNED:	06/22/2022
Total Attachments: 6	
source=Assignment#page1.tif	

source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif

ASSIGNMENT

WHEREAS, we, Norman R. Wainwright, Masakazu Tsuchiya, John Dubczak, and Foster T. Jordan (each an "ASSIGNOR"), have invented one or more inventions described in an application for Letters Patent of the United States entitled:

HYBRID AMEBOCYTE LYSATE AND USES THEREOF

and identified by Attorney Docket No. **CHR-047**, which was filed in the United States Patent and Trademark Office on **February 11, 2022**, and assigned United States Patent Application No. **17/650,803**, and

WHEREAS, **CHARLES RIVER LABORATORIES, INC.** (hereinafter "ASSIGNEE"), a company organized and existing under the laws of the **State of Delaware** and having a business address at **251 Ballardvale Street, Wilmington, MA, USA, 01887**, desires to acquire an interest therein, in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern, be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we have sold, assigned and transferred and do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, at least as early as the filing date of said application, our entire right, title and interest, which ASSIGNEE accepts, in and throughout the United States of America, its territories and all foreign countries, in and to the invention(s) described in said application, together with our entire right, title and interest, which ASSIGNEE accepts, in and to said application and such Letters Patent as may issue thereon, and applications that claim priority thereto under United States law or international or foreign convention and such Letters Patent (including equivalent granting documents) that may issue thereon, including but not limited to non-U.S., international, non-provisional, continuation, divisional, continuation-in-part, reissue, reexamination, extension, and substitution applications of said application and such Letters Patent, and the right to claim priority to said application for any such applications and Letters Patent, and any right, title and interest we may have in invention(s) and applications to which said application claims priority including U.S. provisional and non-provisional, and non-U.S. and international applications; said invention(s), applications and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all of our rights arising under or pursuant to any and all United States laws and foreign and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment, including all rights to exclude others from practicing the claimed invention(s) and all rights to seek any and all remedies in law or equity, including damages and injunctive relief, for past, present, and future infringement. We hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention(s) and applications, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys

and agents of ASSIGNEE's selection and the right to procure the grant of all Letters Patent to ASSIGNEE in its own name as assignee of our entire right, title and interest therein;

AND, we hereby represent, warrant, and covenant to ASSIGNEE, its successors, assigns and legal representatives, that at the time of execution of this Assignment, except for any rights, titles and/or interests that have arisen to ASSIGNEE under law or that have already been transferred to ASSIGNEE, that we have not made and will not hereafter make any assignment, contract, grant, mortgage, license, or other agreement and/or understanding affecting and/or conflicting with the rights, titles, and interests conveyed herein;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention(s) and applications to said ASSIGNEE, its successors, assigns, and legal representatives, as well as to third parties at the request of Assignee, including the execution of documents (including, without limitation, petitions, specifications, oaths, assignments, disclaimers, declarations and affidavits) relating to non-provisional, substitution, continuation, divisional, continuation-in-part, reissue, reexamination, and corresponding foreign and international patent applications of the aforesaid invention(s) and applications, as requested by Assignee, and generally do everything possible to aid Assignee, its successors, assigns and legal representatives to obtain, record, maintain, and enforce full protection for the invention(s), applications and Letters Patent in all countries, but in each instance at Assignee's reasonable expense;

AND, we hereby further agree to provide documentary evidence and statements or testimony in any interference, derivation or post-grant proceeding, or other proceeding in which said invention(s) or any application or patent directed thereto may be involved;

AND, we hereby authorize ASSIGNEE or its attorneys or agents to insert the correct patent application number and filing date into this assignment, if none is indicated on the date of our execution of this assignment;

AND, Assignor does hereby authorize the Director of the United States Patent and Trademark Office and the appropriately empowered officials of all other governments to record the applications and Letters Patent and title thereto as the property of Assignee, its successors, assigns, or legal representatives in accordance with the terms of this instrument;

AND, we hereby authorize and request the Director of the United States Patent and Trademark Office and the appropriately empowered officials of all other governments to issue such Letters Patent as shall be granted upon said application, or applications based thereon, to said ASSIGNEE, its successors, assigns, or legal representatives.

IN TESTIMONY WHEREOF, we have duly executed on the date(s) set forth below this assignment, along with ASSIGNEE's authorized representative, where each ASSIGNOR and said ASSIGNEE may execute this Assignment in counterparts, in which case each executed counterpart will be considered to be an original.

ASSIGNOR

03 May 2022

Date




Norman R. Wainwright

Witness:

May 3 2022

Date




Signature

Name of Witness: Melissa Sauls

[Remainder of page intentionally left blank]


ASSIGNOR

05 MAY 2022
Date


Masakazu Tsuchiya

Witness:


05 May 2022
Date


Signature
Name of Witness: Elizabeth J. Williams

[Remainder of page intentionally left blank]


ASSIGNOR

03-May-2022
Date


John Dubczak

Witness:

03-MAY-2022
Date



Signature
Name of Witness: Lisa Maria Dubczak

[Remainder of page intentionally left blank]

Assignment
Attorney Docket No.: CHR-047
Page 6 of 6

ASSIGNOR

June 10, 2022
Date


Foster T. Jordan

Witness:

June 10, 2022
Date


Signature
Name of Witness: Melissa Sauls

{Remainder of page intentionally left blank}

ACTIV/115631130.1